{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000064","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-04-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.332340+00:00","generated_at":"2026-05-23T18:58:39.572401+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Cartesian reports Descartes-08 Phase 2b MG data: sustained 12-month benefit, Phase 3 on track","bullets":["Average MG-ADL reduction of 4.8 points at Month 12; 83% maintained clinically meaningful response.","In biologic-naive subgroup (n=7): avg 7.1-point MG-ADL reduction, 57% achieved minimum symptom expression (MG-ADL 0-1) at Month 12.","No new safety signals; no CRS or ICANS; supports outpatient administration without lymphodepleting chemo.","Phase 3 AURORA trial on track to dose first patient in Q2 2025; FDA SPA agreement for trial design."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000064","json":"https://secwatch.observer/filing/0001453687-25-000064.json","markdown":"https://secwatch.observer/filing/0001453687-25-000064.md","text":"https://secwatch.observer/filing/0001453687-25-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000064/0001453687-25-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000064/rnac-20250408.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T18:58:39.572401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}